We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global POC Diagnostics/Testing Market to Reach USD 22.8 Billion by 2025

By LabMedica International staff writers
Posted on 03 May 2019
The global point of care (POC) diagnostics/testing market size is expected to grow at a CAGR of 3.3% over the forecast period 2019-2025 to reach USD 22.8 billion by 2025, driven by the ability of POC tests to render rapid and accurate results at bedside settings and in remote areas. More...
The market growth is being further aided by the adoption of automated laboratory systems and highly integrated solutions that facilitate the diagnostic workflow.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Increasing R&D activities by the key players for introducing novel POC tests and devices for the rapid detection and monitoring of diseases is expected to further boost the growth of the POC testing market. Additionally, the lack of skilled professionals or medical personnel with limited training, especially in diagnostics, who can also easily use these devices is also fueling the growth of the POC diagnostics/testing market. Moreover, the high prevalence of chronic disorders and cancer is resulting in a large customer base adopting cost-effective and immediate diagnostic tests, thereby propelling the growth of the POC diagnostics/testing market. This is further supplemented by a number of favorable initiatives to promote the employment of POC tests in diagnosis and screening procedures.

Based on product, the glucose testing segment dominated the POC diagnostics/testing market in 2018 in terms of revenue due to the high prevalence of diabetes and introduction of a wide variety of glucose meters by companies. The Hb1Ac testing segment is also expected to show a similar trend due to stiff competition for delivering low-cost Hb1Ac tests among the key players in the market. The detection and analysis of circulating tumor cells during cancer progression is expected to help the cancer marker segment achieve the fastest penetration rate over the coming years.

Based on end-user, the clinics segment dominated the POC diagnostics/testing market with the largest revenue share in 2018, due to the employment of a wide range of POC tests. On the other hand, increasing awareness about decentralized tests among patients is driving a lucrative growth in home-based POC testing.

Geographically, the US is likely to dominate the North American POC diagnostics/testing market due to the presence of key players undertaking significant research activities in the country. Also, the POC diagnostics/testing market in Asia Pacific holds significant potential for growth due to continuous developments in the region’s healthcare sector for introducing novel and accurate diagnostic tests.

Related Links:
Research and Markets


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.